A Phase IIa Study of FPF300

JRCT ID: jRCT2051200141

Registered date:01/03/2021

Basic Information

• Recruitment status: Complete
• Health condition(s) or Problem(s) studied: Recurrent epistaxis in Hereditary Hemorrhagic Telangiectasia
• Date of first enrollment: 24/03/2021
• Target sample size: 8
• Study type: Interventional
• Intervention(s): FPF300 is orally administered once daily. The initial daily doses will be started at 25 mg and adjusted the dose depending on the patient's condition.

Outcome(s)

• Primary Outcome: Improvement rate of Epistaxis Severity Score
• Secondary Outcome: Safety etc.

Key inclusion & exclusion criteria

• Age minimum: >= 20age old
• Age maximum: Not applicable
• Gender: Both

Include criteria

1) Patients who have diagnosed as definite HHT by the Curacao criteria
2) Patients who have exceeded 4 points by Epistaxis Severity Score and have epistaxis at least three times a week on average since 4weeks before patient's consent
3) Patients whose age are 20 or older at the time of their consent
4) Patients who adhere to FPF300 risk management system

Exclude criteria

1) Women in pregnancy, breastfeeding or child bearing
Men who wish their partners to become pregnant during the study period
2) Patients who have previously been prescribed the following agents
a) thalidomide and derivatives (lenalidomide and pomalidomide)
b) angiogenesis inhibitors (e.g. bevacizumab, pazopanib)
3) Patients who have the medical history(except for a)) or complications below
a) anemia by reason of other than HHT
b) hemorrhagic disease (e.g. hemophilia) by reason of other than HHT
c) pulmonary embolism / deep vein thrombosis
d) bradycardic arrhythmia
e) heart failure
f) pulmonary hypertension
g) active cancer within 5 years of disease free interval
4) BNP >= 100 pg/mL or NT-pro BNP >= 400 pg/mL
5) Patients who have a high risk of deep vein thrombosis
6) Patients who are positive for hepatitis B antigen, hepatitis C antibody, or HIV antibody

Related Information

• Primary Sponsor: Tochikawa Yoshinaga